查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930149

全球头孢菌素市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Cephalosporin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

头孢菌素市场成长因素

受细菌感染日益增多和广谱抗生素需求不断增长的推动，全球头孢菌素市场呈现稳定成长态势。 2025年，该市场规模为83.2亿美元，预计2026年将成长至87.3亿美元，到2034年将达到136.2亿美元，预测期内复合年增长率（CAGR）为5.72%。北美地区凭藉其先进的医疗基础设施和较高的处方量，在2025年占市场主导地位，市占率达47.05%。

头孢菌素类抗生素是β-内酰胺类抗生素，其作用机转是透过抑制细菌细胞壁合成来杀死细菌。 这些抗生素广泛用于治疗泌尿道感染、呼吸道感染、皮肤和软组织感染、肺炎和脑膜炎等感染性疾病。抗菌素抗药性 (AMR) 的持续出现正在加速新一代头孢菌素类抗生素的研发，这些抗生素对抗药性菌株具有更高的疗效。

市场动态

市场驱动因素

大型製药公司不断推出新产品是市场成长的主要驱动因素。抗生素抗药性的上升迫使各公司加大研发投入，以开发对多重抗药性细菌有效的先进头孢菌素类抗生素，例如头孢洛林和头孢吡肟。

例如，2024 年 4 月，巴塞尔製药公司 (Basilea Farmaceutica) 的 Zebutera（头孢吡肟）获得美国 FDA 批准，用于治疗血流感染、急性细菌性皮肤感染和社区获得性肺炎。 此类批准将显着提振市场需求。

市场限制因子

头孢菌素类抗生素的副作用，特别是胃肠道併发症和过敏反应，正在限制市场成长。此外，有报告指出具有神经毒性，尤其是在老年患者和接受高剂量静脉给药的患者中，这引发了人们对安全性的担忧。

2023年3月，纽西兰药物不良反应委员会指出，头孢菌素类抗生素会引起神经系统副作用，如癫痫发作和脑病，因此建议谨慎用药，并限制其广泛应用。

市场机会

药物递送系统和奈米颗粒製剂的进步带来了巨大的成长机会。目前的研究重点是利用金奈米颗粒和银奈米颗粒将老一代头孢菌素转化为奈米抗生素，以提高疗效、减少给药频率并克服抗药性。

2023年1月，美国国立卫生研究院 (NIH) 的一项研究表明，利用金奈米颗粒可以将无效的头孢菌素类抗生素转化为高效的奈米抗生素，这为市场扩张提供了一条充满希望​​的途径。

市场挑战

强而有力的调控架构对于应对抗菌素抗药性 (AMR) 构成了一项重大挑战。世界各国政府都在积极推动抗菌药物管理计画的实施，以遏止抗生素的滥用。

例如，2024年10月，印度医学研究理事会 (ICMR) 报告称，引起泌尿道感染 (UTI) 的病原体对第三代头孢菌素的抗药性很高，这凸显了处方管理的重要性。

头孢菌素市场趋势

一个关键的市场趋势是联合疗法（将头孢菌素类抗生素与β-内酰胺酶抑制剂联合使用）的使用日益增多，以提高对抗药性感染的临床疗效。此外，由于注射剂起效迅速且能标靶给药，其日益受到青睐，这也影响生产策略。

这一趋势得到了Sands Active公司于2024年6月在斯里兰卡投产的注射用头孢菌素生产厂的支持。

细分市场分析

依代数划分，第三代头孢菌素预计将占领先地位，这得益于其广谱抗菌活性以及在呼吸道和皮肤感染中的广泛应用。

依给药途径划分，口服给药途径预计将显着增长，这得益于其使用方便和患者自我治疗的增加。同时，受医院需求的推动，注射给药途径也呈现强劲成长。

依疾病划分，泌尿道感染占最大占有率，这主要归因于医院获得性泌尿道感染的增加。

依分销管道划分，医院药局占主导地位，这主要得益于其处方量庞大。

区域展望

受医院获得性感染率高企的推动，北美预计将引领市场，2025年市场规模将达到38.9亿美元，2026年将达到40.9亿美元。

由于第二代和第三代头孢菌素类抗生素的消费量不断增长，欧洲预计将占第二大市场。

亚太地区预计将实现最高的复合年增长率，这得益于大规模的原料药生产和不断增长的医疗保健投资。

由于监管框架的完善和生产能力的扩大，拉丁美洲以及中东和非洲预计将实现温和增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要公司产品线分析
  • 抗菌药物治疗指引概要
  • 世卫组织抗药性 "优先病原体" 概要
  • 主要产业动态（併购、合作等）
  • 主要公司新产品发布

第五章 全球市场头孢菌素市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依代划分
    • 第一代
    • 第二代
    • 第三代
    • 第四代
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依疾病划分
    • 泌尿道感染
    • 皮肤和软组织感染
    • 呼吸道感染
    • 脑膜炎
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售药房
    • 线上通路药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第五章 北美头孢菌素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲头孢菌素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 其他地区欧洲

第八章 亚太地区头孢菌素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲头孢菌素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章 中东与非洲头孢菌素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • Pfizer Inc.
    • Sandoz Group AG
    • Merck &Co., Inc.,
    • AbbVie Inc.
    • Bayer AG
    • Astellas Pharma Inc.
    • Shionogi &Co., Ltd
    • Abbott
Product Code: FBI113662

Growth Factors of cephalosporin Market

The global cephalosporin market is demonstrating steady growth, supported by the increasing burden of bacterial infections and the rising demand for broad-spectrum antibiotics. The market was valued at USD 8.32 billion in 2025 and is projected to grow to USD 8.73 billion in 2026, reaching USD 13.62 billion by 2034, registering a CAGR of 5.72% during the forecast period. North America dominated the market with a 47.05% share in 2025, driven by advanced healthcare infrastructure and high prescription volumes.

Cephalosporins are B-lactam antibiotics that inhibit bacterial cell wall synthesis, leading to bacterial cell death. These antibiotics are widely used to treat infections such as urinary tract infections, respiratory infections, skin and soft tissue infections, pneumonia, and meningitis. The continuous emergence of antimicrobial resistance (AMR) has accelerated the development of newer-generation cephalosporins with enhanced efficacy against resistant strains.

Market Dynamics

Market Drivers

The increasing number of new product launches by key pharmaceutical players is a major driver of market growth. Rising antibiotic resistance has compelled companies to invest heavily in R&D to develop advanced cephalosporins such as ceftaroline and ceftobiprole, which are effective against multidrug-resistant bacteria.

For instance, in April 2024, Basilea Pharmaceutica Ltd received U.S. FDA approval for ZEVTERA (ceftobiprole) for bloodstream infections, acute bacterial skin infections, and community-acquired bacterial pneumonia. Such approvals significantly boost market demand.

Market Restraints

The market growth is restrained by adverse effects associated with cephalosporins, including gastrointestinal complications and allergic reactions. Moreover, reports of neurotoxicity, particularly among elderly patients and those receiving high intravenous doses, have raised safety concerns.

In March 2023, New Zealand's Medicines Adverse Reaction Committee highlighted neurological side effects such as seizures and encephalopathy, prompting cautious prescription practices and limiting widespread adoption.

Market Opportunities

Advancements in drug delivery systems and nanoparticle-based formulations present significant growth opportunities. Research studies are focusing on converting older-generation cephalosporins into nano-antibiotics using gold and silver nanoparticles to improve potency, reduce dosage frequency, and overcome resistance.

In January 2023, an NIH study demonstrated that ineffective cephalosporins could be transformed into potent nano-antibiotics using gold nanoparticles, offering a promising avenue for market expansion.

Market Challenges

Strict regulatory frameworks aimed at controlling AMR pose a major challenge. Governments worldwide are enforcing antibiotic stewardship programs to restrict overuse.

For example, in October 2024, the Indian Council of Medical Research (ICMR) reported high resistance levels among UTI-causing pathogens against third-generation cephalosporins, emphasizing the need for controlled prescribing.

Cephalosporin Market Trends

A key market trend is the rising popularity of combination therapies, where cephalosporins are used alongside B-lactamase inhibitors to improve clinical outcomes against resistant infections. Additionally, the growing preference for injectable formulations due to faster action and targeted delivery is shaping production strategies.

In June 2024, Sands Active Ltd. launched a cephalosporin injectable manufacturing plant in Sri Lanka, highlighting this trend.

Segmentation Analysis

By generation, the third-generation cephalosporins segment is expected to dominate due to its broad-spectrum activity and widespread use in respiratory and skin infections.

By route of administration, the oral segment is projected to grow significantly due to ease of use and rising self-medication, while the parenteral segment shows strong growth driven by hospital demand.

By disease indication, urinary tract infections hold the largest share, supported by the rising prevalence of hospital-acquired UTIs.

By distribution channel, hospital pharmacies dominate due to high prescription volumes.

Regional Outlook

North America led the market with a valuation of USD 3.89 billion in 2025 and USD 4.09 billion in 2026, driven by high rates of hospital-acquired infections.

Europe holds the second-largest share due to increased consumption of second- and third-generation cephalosporins.

Asia Pacific is expected to register the highest CAGR, supported by large-scale API production and rising healthcare investments.

Latin America and the Middle East & Africa are anticipated to witness moderate growth owing to improving regulatory frameworks and manufacturing capacity expansion.

Competitive Landscape

The market is semi-consolidated, with key players including Pfizer Inc., Sandoz Group AG, Merck & Co., Inc., AbbVie Inc., GSK plc., Astellas Pharma Inc., and Shionogi & Co., Ltd. These companies focus on R&D investments, strategic collaborations, and capacity expansion to strengthen their market presence.

Conclusion

The global cephalosporin market is expected to grow steadily through 2034, driven by rising bacterial infections, continuous product innovations, and the urgent need to combat antimicrobial resistance. Although adverse effects and strict regulatory controls pose challenges, advancements in combination therapies, nanoparticle-based drug delivery, and injectable formulations are creating new growth opportunities. With North America maintaining dominance and Asia Pacific emerging as a high-growth region, the cephalosporin market is well-positioned for sustained expansion, reinforcing its critical role in modern infectious disease management.

Segmentation

By Generation

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease Indications

  • Urinary Tract Infections
  • Skin & Soft Tissue infection
  • Respiratory Infections
  • Meningitis
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • U.S.
    • Canada
  • Europe (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Generation, Route of Administration, Disease Indications, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Overview of Antimicrobial Treatment Guidelines
  • 4.3. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. New Product Launches, By Key Players

5. Global Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Generation
    • 5.1.1. First Generation
    • 5.1.2. Second Generation
    • 5.1.3. Third Generation
    • 5.1.4. Fourth Generation
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.3.1. Urinary Tract Infections
    • 5.3.2. Skin & Soft Tissue Infections
    • 5.3.3. Respiratory Infections
    • 5.3.4. Meningitis
    • 5.3.5. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Pharmacy
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Generation
    • 6.1.1. First Generation
    • 6.1.2. Second Generation
    • 6.1.3. Third Generation
    • 6.1.4. Fourth Generation
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.3.1. Urinary Tract Infections
    • 6.3.2. Skin & Soft Tissue Infections
    • 6.3.3. Respiratory Infections
    • 6.3.4. Meningitis
    • 6.3.5. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Pharmacy
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Generation
    • 7.1.1. First Generation
    • 7.1.2. Second Generation
    • 7.1.3. Third Generation
    • 7.1.4. Fourth Generation
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.3.1. Urinary Tract Infections
    • 7.3.2. Skin & Soft Tissue Infections
    • 7.3.3. Respiratory Infections
    • 7.3.4. Meningitis
    • 7.3.5. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Pharmacy
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Generation
    • 8.1.1. First Generation
    • 8.1.2. Second Generation
    • 8.1.3. Third Generation
    • 8.1.4. Fourth Generation
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.3.1. Urinary Tract Infections
    • 8.3.2. Skin & Soft Tissue Infections
    • 8.3.3. Respiratory Infections
    • 8.3.4. Meningitis
    • 8.3.5. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Pharmacy
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Generation
    • 9.1.1. First Generation
    • 9.1.2. Second Generation
    • 9.1.3. Third Generation
    • 9.1.4. Fourth Generation
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.3.1. Urinary Tract Infections
    • 9.3.2. Skin & Soft Tissue Infections
    • 9.3.3. Respiratory Infections
    • 9.3.4. Meningitis
    • 9.3.5. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Pharmacy
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cephalosporin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Generation
    • 10.1.1. First Generation
    • 10.1.2. Second Generation
    • 10.1.3. Third Generation
    • 10.1.4. Fourth Generation
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.3.1. Urinary Tract Infections
    • 10.3.2. Skin & Soft Tissue Infections
    • 10.3.3. Respiratory Infections
    • 10.3.4. Meningitis
    • 10.3.5. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sandoz Group AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.,
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AbbVie Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Bayer AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Astellas Pharma Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Shionogi & Co., Ltd
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Abbott
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 2: Global Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 4: Global Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Cephalosporin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 7: North America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 9: North America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Cephalosporin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 11: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 12: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 14: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 17: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 19: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 21: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 22: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 24: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Generation, 2021-2034
  • Table 27: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 29: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Cephalosporin Market Revenue (USD billion) Forecast, by Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Cephalosporin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cephalosporin Market Value Share (%), by Generation, 2025 & 2034
  • Figure 3: Global Cephalosporin Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Cephalosporin Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 5: Global Cephalosporin Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Cephalosporin Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 8: North America Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 9: North America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Cephalosporin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 16: North America Cephalosporin Market Value Share (%), by Country, 2025
  • Figure 17: Europe Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 18: Europe Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 19: Europe Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 22: Europe Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 23: Europe Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 26: Europe Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 27: Asia Pacific Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 28: Asia Pacific Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 29: Asia Pacific Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 33: Asia Pacific Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 36: Asia Pacific Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 37: Latin America Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 38: Latin America Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 39: Latin America Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 42: Latin America Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 46: Latin America Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 47: Middle East & Africa Cephalosporin Market Value (USD billion), by Generation, 2025 & 2034
  • Figure 48: Middle East & Africa Cephalosporin Market Value Share (%), by Generation, 2025
  • Figure 49: Middle East & Africa Cephalosporin Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Cephalosporin Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Cephalosporin Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cephalosporin Market Value Share (%), by Disease Indication, 2025
  • Figure 53: Middle East & Africa Cephalosporin Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Cephalosporin Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Cephalosporin Market Value (USD billion), by Country/Sub-Region, 2025 & 2034
  • Figure 56: Middle East & Africa Cephalosporin Market Value Share (%), by Country/Sub-Region, 2025
  • Figure 57: Global Cephalosporin Market Share (%), by Company, 2025